公开(公告)号：US20250009717A1

公开(公告)日：2025-01-09

申请号：US18672743

申请日：2024-05-23

Applicant: Stealth BioTherapeutics Inc.

Inventor： Dennis Keefe ,  Guozhu Zheng ,  Vania Broccoli

IPC: A61K31/4245 ,  A61K31/135 ,  A61K31/197 ,  A61K31/4152 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/5513 ,  A61K38/30 ,  A61P25/28

Abstract: The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. The present disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondria-targeting peptidomimetic compound, such as (R)-2-amino-N-((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof.

公开(公告)号：US12049455B2

公开(公告)日：2024-07-30

申请号：US18087890

申请日：2022-12-23

Applicant: Stealth BioTherapeutics Inc.

Inventor： Dennis Keefe ,  Guozhu Zheng ,  Pavels Arsenjans

IPC: C07D305/10 ,  C07C49/835

CPC classification number: C07D305/10 ,  C07C49/835

Abstract: The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).

公开(公告)号：US20240092832A1

公开(公告)日：2024-03-21

申请号：US18120648

申请日：2023-03-13

Applicant: Stealth BioTherapeutics Inc.

Inventor： Guozhu Zheng

IPC: C07K5/107 ,  A61P13/12

CPC classification number: C07K5/1016 ,  A61P13/12 ,  A61K38/00

Abstract: Disclosed are deuterated analogs of SBT-20 and elamipretide (MTP-131). The compounds are useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

公开(公告)号：US12037350B2

公开(公告)日：2024-07-16

申请号：US17221463

申请日：2021-04-02

Applicant: Stealth BioTherapeutics Inc.

Inventor： Dennis Keefe ,  Guozhu Zheng

IPC: C07F7/08 ,  C07C43/23 ,  C07C50/28

CPC classification number: C07F7/081 ,  C07C43/23 ,  C07C50/28

Abstract: The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).

公开(公告)号：US12016843B2

公开(公告)日：2024-06-25

申请号：US17689666

申请日：2022-03-08

Applicant: Stealth BioTherapeutics Inc.

Inventor： Dennis Keefe ,  Guozhu Zheng ,  Vania Broccoli

IPC: A61K31/4245 ,  A61K31/135 ,  A61K31/197 ,  A61K31/4152 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/5513 ,  A61K38/30 ,  A61P25/28

CPC classification number: A61K31/4245 ,  A61K31/135 ,  A61K31/197 ,  A61K31/4152 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/5513 ,  A61K38/30 ,  A61P25/28

Abstract: The present disclosure provides novel methods for treating or preventing amyotrophic lateral sclerosis (ALS), methods for delaying the onset of neurological symptoms associated with ALS, increasing survival in subjects afflicted with ALS, and attenuating the decline of muscle strength associated with ALS in a subject in need thereof. The present disclosure also provides methods for treating or preventing α-synucleinopathy or TDP-43 proteinopathy. The methods comprise administering to the subject an effective amount of a mitochondria-targeting peptidomimetic compound, such as (R)-2-amino-N—((S)-1-(((S)-5-amino-1-(3-benzyl-1,2,4-oxadiazol-5-yl)pentyl)amino)-3-(4-hydroxy-2,6-dimethylphenyl)-1-oxopropan-2-yl)-5-guanidinopentanamide, or a pharmaceutically acceptable salt, stereoisomer, tautomer, hydrate, and/or solvate thereof.

公开(公告)号：US20230303506A1

公开(公告)日：2023-09-28

申请号：US18087890

申请日：2022-12-23

Applicant: Stealth BioTherapeutics Inc.

Inventor： Dennis Keefe ,  Guozhu Zheng ,  Pavels Arsenjans

IPC: C07D305/10 ,  C07C49/835

CPC classification number: C07D305/10 ,  C07C49/835

Abstract: The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).

公开(公告)号：US20230279052A1

公开(公告)日：2023-09-07

申请号：US18011354

申请日：2021-06-22

Applicant: Stealth Biotherapeutics Inc.

Inventor： Guozhu Zheng ,  Pavels Arsenjans

IPC: C07K5/12 ,  C07K5/107

CPC classification number: C07K5/126 ,  C07K5/1016

Abstract: Disclosed are various prodrugs of L-Phe-D-Arg-L-Phe-L-Lys-NH2.

公开(公告)号：US20240400588A1

公开(公告)日：2024-12-05

申请号：US18672819

申请日：2024-05-23

Applicant: Stealth BioTherapeutics Inc.

Inventor： Dennis Keefe ,  Guozhu Zheng

IPC: C07F7/08 ,  C07C43/23 ,  C07C50/28

Abstract: The disclosure provides therapeutic compounds, compositions (e.g., therapeutic agents or medicaments) and methods for preventing or treating mitochondrial disease such as Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with mitochondrial disease, such as Friedreich's ataxia, and/or reducing the likelihood or severity of mitochondrial disease such as Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions. In some instances, the intermediates may themselves by therapeutic agents or prodrugs of therapeutic agents (e.g. reduced forms of the therapeutic compounds).

公开(公告)号：US20230227499A1

公开(公告)日：2023-07-20

申请号：US18011358

申请日：2021-06-22

Applicant: Stealth Biotherapeutics Inc.

Inventor： Guozhu Zheng ,  Pavels Arsenjans

IPC: C07K5/11 ,  C07K5/107

CPC classification number: C07K5/1019 ,  C07K5/1016

Abstract: Disclosed are various prodrugs of Elamipretide.

公开(公告)号：US11584728B2

公开(公告)日：2023-02-21

申请号：US17062339

申请日：2020-10-02

Applicant: STEALTH BIOTHERAPEUTICS INC.

Inventor： Dennis Keefe ,  Guozhu Zheng ,  Pavels Arsenjans

IPC: C07C49/835 ,  C07D305/10

Abstract: The disclosure provides therapeutic compositions (i.e., therapeutic agents) and methods of preventing or treating Friedreich's ataxia in a mammalian subject, reducing risk factors, signs and/or symptoms associated with Friedreich's ataxia (e.g., Complex I deficiency), and/or reducing the likelihood or severity of Friedreich's ataxia. The disclosure further provides novel intermediates for the production of said therapeutic compositions and related reduced versions of said therapeutic compositions, which reduce forms may also be used as therapeutic agents (or prodrugs of the therapeutic agent(s)).